A dengue vaccine from Sanofi was approved in the U.S.
Sanofi SA’s dengue vaccine was approved in the U.S., the first treatment cleared by American regulators to protect against the mosquito-borne viral infection.
The vaccine, Dengvaxia, was approved by the Food and Drug Administration to treat people aged 9 to 16 with a laboratory-confirmed prior infection who live in areas where the disease occurs regularly through the year.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Sanofi wins U.S. approval to sell dengue vaccine but with major restrictionsThe U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue ...
Leer más »
Sanofi wins U.S. approval to sell dengue vaccine but with major restrictionsThe U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue ...
Leer más »
Shares of Bausch Health, formerly Valeant, rise 3% on FDA approval of psoriasis treatmentBausch Health, formerly known as Valeant Pharmaceuticals, said Thursday that it and its dermatology business, Ortho Dermatologics received approval from the FDA for a lotion to treat plaque psoriasis.
Leer más »
Bolton gets testy when pressed about Trump getting tough on RussiaAn interview with national security adviser John Bolton briefly went off the rails when Bolton accused his interviewer of attempting to steer the discussion about an uprising in Venezuela to Russian collusion
Leer más »
Merck steps up U.S. measles vaccine production with increased demandMerck & Co said on Wednesday it has increased production of the measles vaccine ...
Leer más »
'Only medical exemptions': Buttigieg campaign clarifies vaccine position after uproarButtigieg's campaign tried to clarify the mayor's position on vaccines after earlier comments indicated support for personal or religious exemptions.
Leer más »
Merck raises full-year forecasts as vaccines power profit beatMerck & Co Inc reported higher-than-expected first-quarter profit on Tuesday on ...
Leer más »